RxDoctor Payments Data

Stephen Goldner, MD

Internal Medicine · Bluffton, SCNPI 1710087614

Payments from drug & device makers

$1,009in general payments, 2019–2025

Across 64 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$321
  • Pfizer$194
  • Lilly USA, LLC$92
  • Abbott$83
  • Kowa Pharmaceuticals America, Inc.$70
  • GSK$61
  • plus $188 from 8 others

What the payments were for

  • Food & beverage$99999%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,009 in reported general payments places this provider in the 65th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$330,225
Medicare patients
798
Services billed
3,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide204$271,708
JardianceEmpagliflozin114$160,549
TrulicityDulaglutide96$149,961
EliquisApixaban102$144,101
RybelsusSemaglutide27$59,998
OzempicSemaglutide40$58,620
XareltoRivaroxaban19$29,917
MyrbetriqMirabegron23$18,250
Valsartan475$12,508
Rosuvastatin Calcium991$11,696
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,001
Nebivolol Hcl119$9,656
Levothyroxine Sodium609$9,113
SynthroidLevothyroxine Sodium104$8,386
LivaloPitavastatin Calcium12$8,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$92$421,669300 claims
Boehringer IngelheimJardiance$14$160,549114 claims
PfizerEliquis$194$144,101102 claims
Novo NordiskRybelsus, Ozempic$321$118,61967 claims
GSKTrelegy Ellipta$61$11,00117 claims
AbbVieSynthroid$17$8,386104 claims
Kowa Pharmaceuticals America, Inc.Livalo$70$8,04412 claims
AstraZenecaFarxiga$37$6,07211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Bluffton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →